According to the association of both CRC CSC markers’ expression, the mean OS for patients with low CD133 and CD166 tumor expression was 39.43 ± 18.40 months, and it was 35.33 ± 17.42 months for patients with high CD133 and CD166 tumor expression. This evidence concerns the gene ALCAM and neoplasm.